A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
Clinical trial NCT07118254 · RECRUITING
Trial details
- NCT number
- NCT07118254
- Sponsor
- Lubris Bio Pty Ltd
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-17
- Primary completion
- 2026-09-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.